Alkermes (ALKS) Revenue & Revenue Breakdown
Alkermes Revenue Highlights
Latest Revenue (Y)
$1.66B
Latest Revenue (Q)
$399.13M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Alkermes Revenue by Period
Alkermes Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.66B | 49.61% |
| 2022-12-31 | $1.11B | -5.28% |
| 2021-12-31 | $1.17B | 13.00% |
| 2020-12-31 | $1.04B | -11.29% |
| 2019-12-31 | $1.17B | 7.01% |
| 2018-12-31 | $1.09B | 21.13% |
| 2017-12-31 | $903.37M | 21.15% |
| 2016-12-31 | $745.69M | 18.68% |
| 2015-12-31 | $628.34M | 1.54% |
| 2014-12-31 | $618.79M | 7.51% |
| 2013-03-31 | $575.55M | 47.59% |
| 2012-03-31 | $389.98M | 108.95% |
| 2011-03-31 | $186.64M | 4.69% |
| 2010-03-31 | $178.28M | -45.45% |
| 2009-03-31 | $326.84M | 35.78% |
| 2008-03-31 | $240.72M | 0.31% |
| 2007-03-31 | $239.97M | 44.04% |
| 2006-03-31 | $166.60M | 118.85% |
| 2005-03-31 | $76.13M | 94.92% |
| 2004-03-31 | $39.05M | -17.37% |
| 2003-03-31 | $47.27M | -12.63% |
| 2002-03-31 | $54.10M | -3.44% |
| 2001-03-31 | $56.03M | 144.45% |
| 2000-03-31 | $22.92M | -47.57% |
| 1999-03-31 | $43.72M | 39.55% |
| 1998-03-31 | $31.33M | 58.00% |
| 1997-03-31 | $19.83M | 41.62% |
| 1996-03-31 | $14.00M | 13.82% |
| 1995-03-31 | $12.30M | 57.69% |
| 1994-03-31 | $7.80M | -17.89% |
| 1993-03-31 | $9.50M | - |
Alkermes generated $1.66B in revenue during NA 2023, up 49.61% compared to the previous quarter, and up 152.01% compared to the same period a year ago.
Alkermes Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $399.13M | 13.92% |
| 2024-03-31 | $350.37M | -7.18% |
| 2023-12-31 | $377.48M | -0.91% |
| 2023-09-30 | $380.94M | -38.30% |
| 2023-06-30 | $617.40M | 114.68% |
| 2023-03-31 | $287.60M | -5.61% |
| 2022-12-31 | $304.67M | 20.73% |
| 2022-09-30 | $252.36M | -8.64% |
| 2022-06-30 | $276.22M | -0.84% |
| 2022-03-31 | $278.55M | -14.15% |
| 2021-12-31 | $324.46M | 10.31% |
| 2021-09-30 | $294.14M | -3.15% |
| 2021-06-30 | $303.72M | 20.80% |
| 2021-03-31 | $251.43M | -10.20% |
| 2020-12-31 | $280.00M | 5.65% |
| 2020-09-30 | $265.01M | 7.06% |
| 2020-06-30 | $247.53M | 0.53% |
| 2020-03-31 | $246.22M | -40.34% |
| 2019-12-31 | $412.73M | 61.70% |
| 2019-09-30 | $255.24M | -8.80% |
| 2019-06-30 | $279.87M | 25.45% |
| 2019-03-31 | $223.10M | -29.34% |
| 2018-12-31 | $315.76M | 26.95% |
| 2018-09-30 | $248.72M | -18.36% |
| 2018-06-30 | $304.64M | 35.31% |
| 2018-03-31 | $225.15M | -18.24% |
| 2017-12-31 | $275.37M | 26.67% |
| 2017-09-30 | $217.38M | -0.67% |
| 2017-06-30 | $218.84M | 14.11% |
| 2017-03-31 | $191.78M | -10.18% |
| 2016-12-31 | $213.51M | 18.46% |
| 2016-09-30 | $180.24M | -7.65% |
| 2016-06-30 | $195.16M | 24.49% |
| 2016-03-31 | $156.77M | -3.88% |
| 2015-12-31 | $163.10M | 6.84% |
| 2015-09-30 | $152.65M | 0.85% |
| 2015-06-30 | $151.37M | -6.11% |
| 2015-03-31 | $161.21M | -7.96% |
| 2014-12-31 | $175.16M | 9.48% |
| 2014-09-30 | $159.99M | 4.28% |
| 2014-06-30 | $153.42M | 17.83% |
| 2014-03-31 | $130.21M | -6.86% |
| 2013-09-30 | $139.80M | 0.84% |
| 2013-06-30 | $138.63M | -15.17% |
| 2013-03-31 | $163.42M | 20.24% |
| 2012-12-31 | $135.91M | 9.62% |
| 2012-09-30 | $123.98M | -18.56% |
| 2012-06-30 | $152.24M | 16.68% |
| 2012-03-31 | $130.47M | 3.84% |
| 2011-12-31 | $125.64M | 74.56% |
| 2011-09-30 | $71.98M | 16.31% |
| 2011-06-30 | $61.88M | 21.01% |
| 2011-03-31 | $51.14M | 16.29% |
| 2010-12-31 | $43.98M | -10.71% |
| 2010-09-30 | $49.25M | 16.48% |
| 2010-06-30 | $42.28M | 9.89% |
| 2010-03-31 | $38.48M | -12.86% |
| 2009-12-31 | $44.15M | -8.32% |
| 2009-09-30 | $48.16M | 1.39% |
| 2009-06-30 | $47.50M | 8.25% |
| 2009-03-31 | $43.88M | -71.81% |
| 2008-12-31 | $155.66M | 229.02% |
| 2008-09-30 | $47.31M | -40.86% |
| 2008-06-30 | $79.99M | 28.18% |
| 2008-03-31 | $62.41M | - |
Alkermes generated $399.13M in revenue during Q2 2024, up 13.92% compared to the previous quarter, and up 138.78% compared to the same period a year ago.
Alkermes Revenue Breakdown
Alkermes Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $920.00M | $777.55M | $627.42M | $524.50M | - |
| Aristada And Aristada Initio | $327.69M | $302.05M | $275.36M | - | - |
| L Y B A L V I | $191.89M | $96.02M | $8.21M | - | - |
| Vivitrol | $400.42M | $379.48M | $343.85M | $335.37M | - |
| Manufactured Product And Royalty | - | - | - | $22.50M | - |
| License | - | - | - | $1.05M | - |
| Research And Development | - | - | - | $1.95M | - |
| Aristada Or Aristada Initio | - | - | - | - | $189.13M |
Alkermes's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (50.00%), Vivitrol (21.76%), Aristada And Aristada Initio (17.81%), and L Y B A L V I (10.43%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aristada And Aristada Initio | $86.05M | $78.87M | $247.61M | $80.08M | $79.23M | $74.62M | $72.48M | $78.66M | $68.87M | $72.39M | $55.43M | - | - | - | - | - | - | - | - | - |
| Vivitrol | $111.87M | $97.66M | $303.76M | $96.66M | $101.98M | $96.11M | $84.85M | $92.04M | $88.86M | $88.42M | $74.53M | $71.65M | $78.77M | $85.16M | - | - | - | - | - | - |
| Product | $269.27M | $233.54M | $705.27M | $214.73M | $216.12M | $190.79M | $171.27M | $178.92M | $157.74M | $160.81M | $129.96M | $148.96M | $142.66M | $130.41M | $129.73M | $138.77M | $136.63M | - | - | - |
| L Y B A L V I | $71.35M | $57.01M | $153.90M | $37.99M | $34.91M | $20.06M | $13.93M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Manufacturing Revenue | - | - | - | $40.62M | $31.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.05M | $144.75M | $1.00M | - | - | - |
| Research And Development | - | - | - | - | - | - | - | - | - | - | - | - | - | $141.00K | $953.00K | $11.08M | $14.34M | - | - | - |
| Aristada Or Aristada Initio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $58.77M | $50.96M | - | - | - |
| License And Service | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.00M | - | - |
| Aristada | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $53.61M | - |
| Manufactured Product And Royalty | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $127.90M |
Alkermes's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (50.00%), Vivitrol (20.77%), Aristada And Aristada Initio (15.98%), and L Y B A L V I (13.25%).
Alkermes Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Foreign Country Excluding Specified Country | $170.29M | $177.97M | $187.34M | $196.53M | $200.82M |
| UNITED STATES | $1.49B | $931.99M | $984.24M | $839.00M | $966.93M |
| IRELAND | $1.18M | $1.83M | $2.17M | $3.23M | $3.19M |
Alkermes's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (89.69%), Foreign Country Excluding Specified Country (10.24%), and IRELAND (0.07%).
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L Y B A L V I | $37.99M | $34.91M | $20.06M | $13.93M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Aristada And Aristada Initio | $80.08M | $79.23M | $74.62M | $72.48M | $78.66M | $68.87M | $72.39M | $55.43M | - | - | - | - | - | - | - | - | - | - | - | - |
| Vivitrol | $96.66M | $101.98M | $96.11M | $84.85M | $92.04M | $88.86M | $88.42M | $74.53M | $71.65M | $78.77M | $85.16M | $83.83M | $79.89M | $76.20M | - | - | - | - | - | - |
| Product | $214.73M | $216.12M | $190.79M | $171.27M | $178.92M | $157.74M | $160.81M | $129.96M | $148.96M | $142.66M | $130.41M | $129.73M | $138.77M | $136.63M | $99.48M | - | - | - | - | - |
| Research And Development | - | - | - | - | - | - | - | - | $141.00K | $953.00K | $11.08M | $14.34M | $14.71M | $1.50M | - | - | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | $1.05M | $144.75M | $1.00M | $48.30M | - | - | - | - | - | - | - |
| Aristada Or Aristada Initio | - | - | - | - | - | - | - | - | - | - | $58.77M | $50.96M | - | - | - | - | - | - | - | - |
| License And Service | - | - | - | - | - | - | - | - | - | - | - | - | $5.00M | - | - | - | - | - | - | - |
| Aristada | - | - | - | - | - | - | - | - | - | - | - | - | - | $53.61M | $48.82M | $36.14M | $33.60M | - | - | - |
| Manufactured Product And Royalty | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $127.90M | $108.92M | $114.60M | - | - | - |
| Clinical Supply | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $200.00K | - | - | - |
| R I S P E R D A L C O N S T A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.32M | - | - |
| A M P Y R A Or F A M P Y R A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.45M | - | - |
| B Y D U R E O N | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.94M | - | - |
| Invega Sustenna Or Xeplion And Invega Trinza | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $65.62M | - | - |
| Other Products And Services | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.89M | - | - |
Alkermes's latest quarterly revenue breakdown by geography, as of Mar 23: Product (50.00%), Vivitrol (22.51%), Aristada And Aristada Initio (18.65%), and L Y B A L V I (8.85%).
Alkermes Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $73.80M |
| EOLS | Evolus | $199.72M | $66.22M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
ALKS Revenue FAQ
What is Alkermes’s yearly revenue?
Alkermes's yearly revenue for 2023 was $1.66B, representing an increase of 49.61% compared to 2022. The company's yearly revenue for 2022 was $1.11B, representing a decrease of -5.28% compared to 2021. ALKS's yearly revenue for 2021 was $1.17B, representing an increase of 13.00% compared to 2020.
What is Alkermes’s quarterly revenue?
Alkermes's quarterly revenue for Q2 2024 was $399.13M, a 13.92% increase from the previous quarter (Q1 2024), and a -35.35% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $350.37M, a -7.18% decrease from the previous quarter (Q4 2023), and a 21.83% increase year-over-year (Q1 2023). ALKS's quarterly revenue for Q4 2023 was $377.48M, a -0.91% decrease from the previous quarter (Q3 2023), and a 23.89% increase year-over-year (Q4 2022).
What is Alkermes’s revenue growth rate?
Alkermes's revenue growth rate for the last 3 years (2021-2023) was 41.72%, and for the last 5 years (2019-2023) was 42.06%.
What are Alkermes’s revenue streams?
Alkermes's revenue streams in c 23 are Product, Aristada And Aristada Initio, L Y B A L V I, and Vivitrol. Product generated $920M in revenue, accounting 50.00% of the company's total revenue, up 18.32% year-over-year. Aristada And Aristada Initio generated $327.69M in revenue, accounting 17.81% of the company's total revenue, up 8.49% year-over-year. L Y B A L V I generated $191.89M in revenue, accounting 10.43% of the company's total revenue, up 99.84% year-over-year. Vivitrol generated $400.42M in revenue, accounting 21.76% of the company's total revenue, up 5.52% year-over-year.
What is Alkermes’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Alkermes was Product. This segment made a revenue of $920M, representing 50.00% of the company's total revenue.